Replies to post #226373 on Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

"One thing is clear - in Biotechs, 95-99% of the times delay is bad news."

I'll take that as your opinion, as you do not sight a source. Fair enough.

Compare your quote to Eli Lilly's phase 2 Taltz study. Start date April, 2010. Primary completion date January, 2011(# patients=142).
Announcement of primary endpoint achievement, 3/29/12. Time for Eli Lilly to announce first endpoint(of 32 total endpoints(2 pe,30 sop)) in that trial was ~440 days. Eli Lillys product, Taltz. has been approved for the same target ipix is focusing on.

https://psoriasisclub.org/thread-638.html

https://clinicaltrials.gov/ct2/show/NCT01107457?term=ixekizumab&recrs=e&rslt=With&age=12&phase=1&rank=1

Lilly's analysis was much more detailed, with the 22nd endpoint being the longest(344 weeks(6.6 years)).

To date, psoriasis has been incurable(even given the taltz approval-responses vary-widely), and likely will continue to be for the foreseeable future.

Most past approved psoriasis drugs suffice for a limited time before a patient seeks another remedy due to diminishing results, or worsening ones.